Bristol-Myers Squibb: HIV Infections trials

The registry lists 64 HIV Infections studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 18Phase 2 6Phase 3 18Phase 4 5No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With CobicistatCompletedNCT01837719Phase 1Results posted
• PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)CompletedNCT01099579Phase 3Results posted
• Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy ParticipantsCompletedNCT00833482Phase 1Results posted
• Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected ChildrenCompletedNCT00364793Phase 1/2Results posted
• Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic SuppressionCompletedNCT00337467Phase 3Results posted
• Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant WomenCompletedNCT00326716Phase 1Results posted
• BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose TruvadaCompletedNCT00272779Phase 3Results posted
• Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)CompletedNCT00207142Phase 4Results posted
• Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIVCompletedNCT00035932Phase 3Results posted
• A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)CompletedNCT03407105Phase 1
• A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WithdrawnNCT02556086Phase 2
• Risk of CV Events With EFV vs. EFV-free RegimensCompletedNCT02426866
• Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy SubjectsCompletedNCT02164812Phase 1
• Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in EuropeCompletedNCT01389310
• DDI HV (ATV - Merck)CompletedNCT00518297Phase 1
• Drug Interaction - Oral ContraceptiveCompletedNCT00399685Phase 1
• A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected SubjectsWithdrawnNCT00397566Phase 2
• Bioequivalence Study of Atazanavir 300 mg CapsuleCompletedNCT00393328Phase 1
• Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected PatientsCompletedNCT00384904Phase 4
• Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/TenofovirCompletedNCT00365339Phase 1
• Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate RosiglitazoneCompletedNCT00362726Phase 1
• Atazanavir Twice DailyCompletedNCT00357721Phase 1
• Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy FemalesCompletedNCT00357604Phase 1
• Drug Interaction Study With Proton Pump InhibitorCompletedNCT00357240Phase 1
• Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy SubjectsCompletedNCT00357188Phase 1
• A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic SyndromeTerminatedNCT00312754Phase 4
• An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV InfectionNo longer availableNCT00162227
• An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: CanadaNo longer availableNCT00162188
• ATV/Ritonavir Nevirapine Interaction (USPAC)CompletedNCT00162149Phase 1
• A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the RegimenCompletedNCT00135447
• Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin MetabolismCompletedNCT00135434Phase 1
• A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART RegimenCompletedNCT00135395Phase 3
• Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based RegimenCompletedNCT00135382Phase 3
• Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily RegimenCompletedNCT00135369Phase 3
• A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing RegimenCompletedNCT00135343Phase 3
• Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/RitonavirCompletedNCT00120393Phase 3
• DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral TherapyCompletedNCT00116415Not applicable
• Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)CompletedNCT00116298Phase 3
• DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral TherapyCompletedNCT00116116Phase 4
• Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected SubjectsCompletedNCT00096746
• Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive PatientsCompletedNCT00084253Phase 4
• A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral TherapyCompletedNCT00067782Phase 3
• Atazanavir for HIV Infected Individuals: An Early Access ProgramNo longer availableNCT00046345
• Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)CompletedNCT00028301Phase 3
• A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease InhibitorTerminatedNCT00028067Phase 3
• A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-LamivudineCompletedNCT00013897Phase 3
• Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected PatientsCompletedNCT00005918Phase 3
• Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous TreatmentCompletedNCT00004584Phase 2
• Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug RegimenCompletedNCT00002429Phase 3
• The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsTerminatedNCT00002420Phase 2
• A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV DrugsCompletedNCT00002411Not applicable
• The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken ZidovudineCompletedNCT00002371Phase 3
• A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsCompletedNCT00002369Not applicable
• A Study Comparing Two Forms of Didanosine in HIV-infected PatientsCompletedNCT00002360Phase 1
• A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.CompletedNCT00002349Not applicable
• A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV DrugsCompletedNCT00002308Not applicable
• A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected PatientsCompletedNCT00002307Not applicable
• Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV DrugsCompletedNCT00002240Phase 2
• Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)CompletedNCT00002224Phase 3
• A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected PatientsCompletedNCT00002207Not applicable
• A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV InfectionCompletedNCT00002177Not applicable
• A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV InfectionCompletedNCT00002176Not applicable
• A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected PatientsCompletedNCT00002168Not applicable
• A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)CompletedNCT00002028Not applicable